Pre-emptive treatment of heart failure exacerbations in patients managed with the HeartLogic™ algorithm.
Connected devices
Heart failure
Hospitalization
Mortality
Pre-emptive action
Prediction
Remote monitoring
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
17 Jan 2024
17 Jan 2024
Historique:
revised:
21
10
2023
received:
17
08
2023
accepted:
20
11
2023
medline:
18
1
2024
pubmed:
18
1
2024
entrez:
18
1
2024
Statut:
aheadofprint
Résumé
Heart failure (HF) is a chronic disease affecting 64 million people worldwide and places a severe burden on society because of its mortality, numerous re-hospitalizations and associated costs. HeartLogic™ is an algorithm programmed into implanted devices incorporating several biometric parameters which aims to predict HF episodes. It provides an index which can be monitored remotely, allowing pre-emptive treatment of congestion to prevent acute decompensation. We aim to assess the impact and security of pre-emptive HF management, guided by the HeartLogic™ index. The HeartLogic™ France Cohort Study is an investigator-initiated, prospective, multi-centre, non-randomized study. Three hundred ten patients with a history of HF (left ventricular ejection fraction ≤40%; or at least one episode of clinical HF with elevated NT-proBNP ≥450 ng/L) and implanted with a cardioverter defibrillator enabling HeartLogic™ index calculation will be included across 10 French centres. The HeartLogic™ index will be monitored remotely for 12 months and in the event of a HeartLogic™ index ≥16, the local investigator will contact the patient for assessment and adjust HF treatment as necessary. The primary endpoint is unscheduled hospitalization for HF. Secondary endpoints are all-cause mortality, cardiovascular death, HF-related death, unscheduled hospitalizations for ventricular or atrial arrhythmia and HeartLogic™ index evolution over time. Blood samples will be collected for biobanking, and quality of life will be assessed. Finally, the safety of a HeartLogic™-triggered strategy for initiating or increasing diuretic therapy will be assessed. A blind and independent committee will adjudicate the events. The HeartLogic™ France Cohort Study will provide robust real-world data in a cohort of HF patients managed with the HeartLogic™ algorithm allowing pre-emptive treatment of heart failure exacerbations.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Boston Scientific through an Investigator-Sponsored Research Program
Informations de copyright
© 2024 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: A systematic analysis for the global burden of disease study 2017. Lancet 2018;392:1789-1858. doi:10.1016/S0140-6736(18)32279-7
Jones NR, Roalfe AK, Adoki I, Hobbs FDR, Taylor CJ. Survival of patients with chronic heart failure in the community: A systematic review and meta-analysis. Eur J Heart Fail 2019;21:1306-1325. doi:10.1002/ejhf.1594
Dharmarajan K, Hsieh AF, Lin Z, Bueno H, Ross JS, Horwitz LI, et al. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA 2013;309:355-363. doi:10.1001/jama.2012.216476
Urbich M, Globe G, Pantiri K, Heisen M, Bennison C, Wirtz HS, et al. A systematic review of medical costs associated with heart failure in the USA (2014-2020). Pharmacoeconomics 2020;38:1219-1236. doi:10.1007/s40273-020-00952-0
Boehmer JP, Hariharan R, Devecchi FG, Smith AL, Molon G, Capucci A, et al. A multisensor algorithm predicts heart failure events in patients with implanted devices: Results from the MultiSENSE study. JACC Heart Fail 2017;5:216-225. doi:10.1016/j.jchf.2016.12.011
Capucci A, Santini L, Favale S, Pecora D, Petracci B, Calò L, et al. Preliminary experience with the multisensor HeartLogic algorithm for heart failure monitoring: A retrospective case series report. ESC Heart Fail 2019;6:308-318. doi:10.1002/ehf2.12394
Treskes RW, Beles M, Caputo M-L, Cordon A, Biundo E, Maes E, et al. Clinical and economic impact of HeartLogic™ compared with standard care in heart failure patients. ESC Heart Fail 2021;8:1541-1551. doi:10.1002/ehf2.13252
Santini L, D'Onofrio A, Dello Russo A, Calò L, Pecora D, Favale S, et al. Prospective evaluation of the multisensor HeartLogic algorithm for heart failure monitoring. Clin Cardiol 2020;43:691-697. doi:10.1002/clc.23366
Calò L, Bianchi V, Ferraioli D, Santini L, Dello Russo A, Carriere C, et al. Full list of participant centers and investigators. Multiparametric implantable cardioverter-defibrillator algorithm for heart failure risk stratification and management: An analysis in clinical practice. Circ Heart Fail 2021;14:e008134. doi:10.1161/CIRCHEARTFAILURE.120.008134
Spertus JA, Jones PG, Sandhu AT, Arnold SV. Interpreting the Kansas City cardiomyopathy questionnaire in clinical trials and clinical care: JACC state-of-the-art review. J Am Coll Cardiol 2020;76:2379-2390. doi:10.1016/j.jacc.2020.09.542
Ferrick AM, Raj SR, Deneke T, Kojodjojo P, Lopez-Cabanillas N, Abe H, et al. 2023 HRS/EHRA/APHRS/LAHRS Expert Consensus Statement on Practical Management of the Remote Device Clinic. Europace. 2023;25:euad123.
Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, et al. Standardized Data Collection for Cardiovascular Trials Initiative (SCTI). 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. Circulation. 2018;137:961-972.
McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004. doi:10.1056/NEJMoa1409077
Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 2018;378:417-427. doi:10.1056/NEJMoa1707855
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599-3726. doi:10.1093/eurheartj/ehab368
Chioncel O, Mebazaa A, Harjola V-P, Coats AJ, Piepoli MF, Crespo-Leiro MG, et al. ESC heart failure long-term registry investigators. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: The ESC heart failure long-term registry. Eur J Heart Fail 2017;19:1242-1254. doi:10.1002/ejhf.890
de Juan Bagudá J, Gavira Gómez JJ, Pachón Iglesias M, Cózar León R, Escolar Pérez V, González Fernández Ó, et al. Remote heart failure management using the HeartLogic algorithm. RE-HEART registry. Rev Esp Cardiol (Engl Ed) 2022;75:709-716. doi:10.1016/j.rec.2021.09.015
Hernandez AF, Albert NM, Allen LA, Ahmed R, Averina V, Boehmer JP, et al. Multiple cArdiac seNsors for mAnaGEment of heart failure (MANAGE-HF) - phase I evaluation of the integration and safety of the HeartLogic multisensor algorithm in patients with heart failure. J Card Fail 2022;28:1245-1254. doi:10.1016/j.cardfail.2022.03.349
Guerra F, D'Onofrio A, De Ruvo E, Manzo M, Santini L, Giubilato G, et al. Decongestive treatment adjustments in heart failure patients remotely monitored with a multiparametric implantable defibrillators algorithm. Clin Cardiol 2022;45:670-678. doi:10.1002/clc.23832
Marijon E, Uy-Evanado A, Dumas F, Karam N, Reinier K, Teodorescu C, et al. Warning symptoms are associated with survival from sudden cardiac arrest. Ann Intern Med 2016;164:23-29. doi:10.7326/M14-2342
Marijon E, Garcia R, Narayanan K, Karam N, Jouven X. Fighting against sudden cardiac death: Need for a paradigm shift-adding near-term prevention and pre-emptive action to long-term prevention. Eur Heart J 2022;43:ehab903. doi:10.1093/eurheartj/ehab903
Garcia R, Warming PE, Narayanan K, Defaye P, Guedon-Moreau L, Blangy H, et al. Dynamic changes in nocturnal heart rate predict short-term cardiovascular events in patients using the wearable cardioverter-defibrillator: From the WEARIT-France cohort study. Europace 2023;25:euad062. doi:10.1093/europace/euad062